• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

埃及原发性骨髓增生异常综合征患者的细胞遗传学特征

Cytogenetic features in primary myelodysplastic syndrome Egyptian patients.

作者信息

Elnahass Yasser, Youssif Lamiaa

机构信息

Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.

Department of Molecular Diagnostics, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City, Menoufia Province, Egypt.

出版信息

J Adv Res. 2018 Feb 7;10:77-83. doi: 10.1016/j.jare.2018.02.002. eCollection 2018 Mar.

DOI:10.1016/j.jare.2018.02.002
PMID:30046476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6057444/
Abstract

Karyotype is the most important diagnostic and prognostic parameter in myelodysplastic syndromes (MDS) and is abnormal in approximately 50% of patients. We emphasized the importance of chromosomal analysis and reported the most frequent cytogenetic abnormalities in 50 MDS (29 males (58%) and 21 females (42%), median age: 57.5 years) Egyptian patients using conventional banding analysis (CBA). Karyotype description was conducted according to the International System for Human Cytogenetic Nomenclature (ISCN, 2013). Patients were diagnosed based on complete history, bone marrow (BM) aspirate, peripheral blood (PBL) examination, and Iron stain. MDS with multilineage dysplasia (MDS-MLD) was the most frequently encountered subtype; 19/50 (38%) followed by MDS with single lineage dysplasia (MDS-SLD); 11/50 (22%). 27/50 patients (54%) showed a normal karyotype while 23 patients (46%) showed clonal nonrandom chromosomal abnormalities. Most patients with MDS with excess blasts-II (MDS-EB-II) showed abnormal karyotype (3/4; 75%) followed by MDS-EB-I (3/5, 60%) and MDS-MLD (10/19, 53%). Among 50 primary MDS patients; 14/50 (28%) had a single chromosomal abnormality, 3/50 (6%) had double chromosomal abnormality, and 6/50 (12%) had complex karyotype. Male sex was more frequently associated with higher IPSS prognostic risk categories than female gender. The most common single chromosomal abnormalities were -5/del5q; 7/50 (14%) patients followed by -7; 4/50 (8%) patients. +8, del20q and delY were each detected in 1/50 patient (2%). Abnormalities of chromosome 5 (-5/del5q) as a single chromosomal abnormality was the most frequent chromosomal abnormality among Egyptian primary MDS patients followed by complex karyotype. Cytogenetic characteristics of MDS Egyptian patients were similar to North African and European patients. Karyotype offers useful information in establishing accurate diagnosis and male gender is an important predisposing factor that can predict worse prognosis in MDS patients.

摘要

核型是骨髓增生异常综合征(MDS)最重要的诊断和预后参数,约50%的患者核型异常。我们强调了染色体分析的重要性,并报告了50例埃及MDS患者(29例男性(58%)和21例女性(42%),中位年龄:57.5岁)使用传统显带分析(CBA)时最常见的细胞遗传学异常。核型描述根据国际人类细胞遗传学命名系统(ISCN,2013)进行。患者根据完整病史、骨髓(BM)穿刺、外周血(PBL)检查和铁染色进行诊断。多系发育异常的MDS(MDS-MLD)是最常见的亚型;19/50(38%),其次是单系发育异常的MDS(MDS-SLD);11/50(22%)。27/50例患者(54%)核型正常,23例患者(46%)显示克隆性非随机染色体异常。大多数伴有过多原始细胞-II的MDS(MDS-EB-II)患者核型异常(3/4;75%),其次是MDS-EB-I(3/5,60%)和MDS-MLD(10/19,53%)。在50例原发性MDS患者中;14/50(28%)有单一染色体异常,3/50(6%)有双重染色体异常,6/50(12%)有复杂核型。男性比女性更常与较高的IPSS预后风险类别相关。最常见的单一染色体异常是-5/del5q;7/50(14%)的患者,其次是-7;4/50(8%)的患者。+8、del20q和delY在1/50例患者(2%)中均有检测到。染色体5异常(-5/del5q)作为单一染色体异常是埃及原发性MDS患者中最常见的染色体异常,其次是复杂核型。埃及MDS患者的细胞遗传学特征与北非和欧洲患者相似。核型在建立准确诊断方面提供了有用信息,男性性别是一个重要的易感因素,可预测MDS患者预后较差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f364/6057444/f976df31a157/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f364/6057444/798336e15b91/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f364/6057444/fabcef4fffaf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f364/6057444/f976df31a157/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f364/6057444/798336e15b91/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f364/6057444/fabcef4fffaf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f364/6057444/f976df31a157/gr2.jpg

相似文献

1
Cytogenetic features in primary myelodysplastic syndrome Egyptian patients.埃及原发性骨髓增生异常综合征患者的细胞遗传学特征
J Adv Res. 2018 Feb 7;10:77-83. doi: 10.1016/j.jare.2018.02.002. eCollection 2018 Mar.
2
Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes.越南原发性骨髓增生异常综合征患者的细胞遗传学特征
Leuk Res Rep. 2022 Aug 12;18:100343. doi: 10.1016/j.lrr.2022.100343. eCollection 2022.
3
[Clinical Characteristics of Myelodysplastic Syndrome with Patients Chromosome 21 Karyotype Abnormality].21号染色体核型异常的骨髓增生异常综合征患者的临床特征
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Oct;29(5):1528-1532. doi: 10.19746/j.cnki.issn.1009-2137.2021.05.024.
4
[Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].[原发性骨髓增生异常综合征患者不同细胞遗传学风险类别的预后意义研究]
Zhonghua Xue Ye Xue Za Zhi. 2011 Dec;32(12):819-24.
5
Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.骨髓增生异常综合征患者血细胞减少症评估中的谱。来自沙特阿拉伯参考中心的报告。
Hematol Oncol Stem Cell Ther. 2022 Jun 1;15(2):39-44. doi: 10.1016/j.hemonc.2020.11.001.
6
[Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].[骨髓增生异常综合征中造血和基质祖细胞的细胞遗传学特征]
Ter Arkh. 2013;85(7):34-42.
7
Cytogenetic characteristics of 665 patients with myelodysplastic syndrome in China: A single-center report.中国665例骨髓增生异常综合征患者的细胞遗传学特征:一项单中心报告。
Oncol Lett. 2021 Feb;21(2):126. doi: 10.3892/ol.2020.12387. Epub 2020 Dec 17.
8
[Analysis of Cytogenetic Characteristics and Clinical Prognosis in 236 Patients with Myelodysplastic Syndrome].236例骨髓增生异常综合征患者的细胞遗传学特征及临床预后分析
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1190-1195. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.032.
9
Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome: The first retrospective cross-sectional study in Iranian patients.成人骨髓增生异常综合征的临床血液学和细胞遗传学谱:伊朗患者的首个回顾性横断面研究。
Mol Cytogenet. 2021 May 8;14(1):24. doi: 10.1186/s13039-021-00548-z.
10
Clinico-Pathological Spectrum and Novel Karyotypic Findings in Myelodysplastic Syndrome: Experience of Tertiary Care Center in India.骨髓增生异常综合征的临床病理谱及新型核型发现:印度三级医疗中心的经验
Mediterr J Hematol Infect Dis. 2017 Aug 16;9(1):e2017048. doi: 10.4084/MJHID.2017.048. eCollection 2017.

引用本文的文献

1
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.从血液系统恶性肿瘤中p53的调控到去调控:对诊断、预后和治疗的影响
Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9.
2
Higher prevalence of poor prognostic markers at a younger age in adult patients with myelodysplastic syndrome - evaluation of a large cohort in India.成人骨髓增生异常综合征患者中年轻患者不良预后标志物的患病率更高——印度一个大型队列的评估
Mol Cytogenet. 2024 Sep 27;17(1):21. doi: 10.1186/s13039-024-00687-z.
3
Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.

本文引用的文献

1
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
2
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.来那度胺治疗对无5q缺失的骨髓增生异常综合征克隆结构的影响。
Blood. 2016 Feb 11;127(6):749-60. doi: 10.1182/blood-2015-04-640128. Epub 2015 Dec 1.
3
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
骨髓增生异常综合征和骨髓增生异常综合征/骨髓增殖性肿瘤:来自发展中国家的真实世界经验。
JCO Glob Oncol. 2024 Feb;10:e2300281. doi: 10.1200/GO.23.00281.
4
Distinct Clinical and Prognostic Features of Myelodysplastic Syndrome in Patients from the Middle East, North Africa, and Beyond: A Systemic Review.中东、北非及其他地区骨髓增生异常综合征患者的独特临床和预后特征:一项系统综述
J Clin Med. 2023 Apr 12;12(8):2832. doi: 10.3390/jcm12082832.
5
Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes.越南原发性骨髓增生异常综合征患者的细胞遗传学特征
Leuk Res Rep. 2022 Aug 12;18:100343. doi: 10.1016/j.lrr.2022.100343. eCollection 2022.
6
LncRNA BC200/miR-150-5p/MYB positive feedback loop promotes the malignant proliferation of myelodysplastic syndrome.长链非编码 RNA BC200/miR-150-5p/MYB 正反馈环促进骨髓增生异常综合征的恶性增殖。
Cell Death Dis. 2022 Feb 8;13(2):126. doi: 10.1038/s41419-022-04578-2.
7
Chromosomal Abnormalities in Myelodysplastic Syndrome Patients in Upper Northern Thailand.泰国北部上游地区骨髓增生异常综合征患者的染色体异常
Asian Pac J Cancer Prev. 2020 Mar 1;21(3):639-645. doi: 10.31557/APJCP.2020.21.3.639.
8
Myelodysplastic syndrome from theoretical review to clinical application view.骨髓增生异常综合征:从理论综述到临床应用视角
Oncol Rev. 2018 Dec 7;12(2):397. doi: 10.4081/oncol.2018.397. eCollection 2018 Jul 4.
来那度胺诱导del(5q)骨髓增生异常综合征中CK1α的泛素化和降解。
Nature. 2015 Jul 9;523(7559):183-188. doi: 10.1038/nature14610. Epub 2015 Jul 1.
4
Recent developments in myelodysplastic syndromes.骨髓增生异常综合征的最新进展。
Blood. 2014 Oct 30;124(18):2793-803. doi: 10.1182/blood-2014-04-522136. Epub 2014 Sep 18.
5
Chromosomal abnormalities in primary myelodysplastic syndrome.原发性骨髓增生异常综合征中的染色体异常
J Coll Physicians Surg Pak. 2014 Sep;24(9):632-5.
6
Myelodysplastic syndromes.骨髓增生异常综合征。
Lancet. 2014 Jun 28;383(9936):2239-52. doi: 10.1016/S0140-6736(13)61901-7. Epub 2014 Mar 21.
7
Morphology, cytogenetics and classification of MDS.骨髓增生异常综合征的形态学、细胞遗传学和分类。
Best Pract Res Clin Haematol. 2013 Dec;26(4):337-53. doi: 10.1016/j.beha.2013.09.004. Epub 2013 Oct 1.
8
Sex difference in myelodysplastic syndrome survival and balance in randomized clinical trials.
J Clin Oncol. 2014 Jan 1;32(1):60-1. doi: 10.1200/JCO.2013.52.5980. Epub 2013 Nov 18.
9
Revised international prognostic scoring system for myelodysplastic syndromes.修订版国际预后积分系统用于骨髓增生异常综合征。
Blood. 2012 Sep 20;120(12):2454-65. doi: 10.1182/blood-2012-03-420489. Epub 2012 Jun 27.
10
Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes.印度初发性骨髓增生异常综合征患者的细胞遗传学特征。
Indian J Med Res. 2011 Oct;134(4):452-7.